Edwards Lifesciences stock gains 1.26 percent near its yearly high

Published on 09/22/2026 at 19:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Edwards Lifesciences stock reached USD 89.45 on September 22, 2026, with a 52-week range of USD 72.30 to USD 96.29. Quarterly EPS was USD 0.78.

Fotorealistisches Katheterlabor mit Chirurgenteam bei minimalinvasivem Herzeingriff — Edwards Lifesciences Herzklappen-OP US28176E1082 im Katheterlabor mit Fluoroskopie-Bildschirmen und Chirurgenteam in Aktion, Illustration mit AI erstellt.

Edwards Lifesciences stock (ISIN US28176E1082) traded at USD 89.45 on the NYSE as of September 22, 2026, up 1.26 percent from the previous close. The price stood below the 52-week high of USD 96.29 and above the 52-week low of USD 72.30, giving the current quote a clear market reference.

Stock remains near yearly high

The September 22, 2026 quote was accompanied by a trading range of USD 88.49 to USD 89.58 and volume of 866,356 shares. The distance from the 52-week high was USD 6.84, while the price remained USD 17.15 above the yearly low, placing the stock closer to its upper than its lower range boundary.

MarketBeat lists a market capitalization of USD 50.80 billion and a consensus price target of USD 100.27 as of September 21, 2026. Its cited target range runs from USD 85.00 to USD 110.00, so the consensus target is USD 11.05 above the September 22 quote.

Quarterly earnings beat estimate

Edwards Lifesciences reported quarterly EPS of USD 0.78 in the latest period cited by MarketBeat, compared with a consensus estimate of USD 0.74. The USD 0.04 beat provides a quantified earnings comparison, while the same source reports year-over-year quarterly revenue growth of 13.6 percent.

The earnings profile remains the key counterweight to the valuation. MarketBeat shows a price-to-earnings ratio of 50.70 and expected earnings growth of 13.00 percent for the coming year, from USD 3.00 to USD 3.39 per share. That comparison places the stock's valuation above the cited market average P/E of about 39.07.

NYSE price and market data

Edwards Lifesciences closed the September 22, 2026 session reference at USD 89.45 on the NYSE, with a daily gain of 1.26 percent. The market capitalization was USD 50.80 billion as of September 21, 2026, while the 52-week range remained USD 72.30 to USD 96.29.